Obstructive Hypertrophic Cardiomyopathy Clinical Trial
Official title:
Coronary Flow Reserve in oHCM Patients Before and After 12 Months of Standard-of-care Mavacamten Treatment as Assessed by PET/CT
The goal of this observational study is to measure the effect of mavacamten treatment on blood flow in the heart muscle (myocardium) in patients with obstructive hypertrophic cardiomyopathy. The main question it aims to answer is: • Does mavacamten treatment improve blood flow in the heart muscle? Participants will take mavacamten at the direction of their treating physician. Participants will complete 2 myocardial Positron Emission Tomography and Computed Tomography (PET-CT) scans. The first scan will be completed before participants start taking mavacamten. The scan will be repeated after 12 months of mavacamten treatment.
This is a single-arm, before-and-after investigation of the effect of mavacamten therapy on myocardial blood flows in adult human subjects prescribed mavacamten for clinical standard of care for oHCM. We hypothesize that 12 months of mavacamten therapy will improve myocardial blood flows as assessed by PET/CT. The investigation will take place at a single site. Participants who consent will be prospectively enrolled once mavacamten therapy has been approved by their health insurance/payer. Enrolled participants will undergo myocardial PET/CT before starting mavacamten and after 12 months of therapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05726799 -
Use of Cryoenergy to Faciltate Myectomy in Hypertrophic Obstructive Cardiomyopathy: Comparison With the Classical Approach
|
||
| Active, not recruiting |
NCT03723655 -
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
|
Phase 2/Phase 3 | |
| Completed |
NCT04603521 -
Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
|
||
| Active, not recruiting |
NCT06211595 -
Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy
|
N/A | |
| Recruiting |
NCT06116968 -
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
|
Phase 3 | |
| Completed |
NCT03470545 -
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
|
Phase 3 | |
| Recruiting |
NCT05879523 -
A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy
|
Phase 1 | |
| Not yet recruiting |
NCT06146660 -
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
|
||
| Recruiting |
NCT05771987 -
Permanent Pacing for Drug-refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
|
N/A | |
| Active, not recruiting |
NCT05174416 -
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
|
Phase 3 | |
| Recruiting |
NCT06224621 -
Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy
|
N/A | |
| Completed |
NCT01631006 -
Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy
|
N/A | |
| Not yet recruiting |
NCT06368037 -
Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy
|
N/A | |
| Recruiting |
NCT05489705 -
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM)
|
||
| Completed |
NCT06354556 -
Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04783766 -
Safety, Tolerability and Pharmacokinetics Study of CK-3773274
|
Phase 1 |